NCT03645577 (YETI-Registry) is a clinical trial in Phrenic Nerve Palsy, sponsored by University of Luebeck.

Who is sponsoring NCT03645577?

NCT03645577 is sponsored by University of Luebeck.

What condition does NCT03645577 study?

NCT03645577 studies Phrenic Nerve Palsy.

Is NCT03645577 still recruiting?

NCT03645577 is currently completed. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT03645577: YETI-Registry

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phrenic Nerve Injury During Pulmonary Vein Isolation With the Second-generation Cryoballoon.

Completed Last updated 29 January 2021

What this trial tests

trial in Phrenic Nerve Palsy in 731 participants. Completed in 30 November 2019.

Timeline

24 July 2018

Primary endpoint
30 November 2019

30 November 2019

Quick facts

Lead sponsor	University of Luebeck
Status	Completed
Study type	OBSERVATIONAL
Enrollment	731
Start date	24 July 2018
Primary completion	30 November 2019
Estimated completion	30 November 2019
Sites	1 location across Germany

Conditions studied

Phrenic Nerve Palsy — all drugs for Phrenic Nerve Palsy →

Sponsor

University of Luebeck

Who can join

18 and older, any sex, with Phrenic Nerve Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the most frequent complication associated with cryoballoon PVI. The main hypothesis is to explore the incidence of phrenic nerve palsy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Phrenic Nerve Injury During Cryoballoon-Based Pulmonary Vein Isolation: Results of the Worldwide YETI Registry.
Heeger CH, Sohns C, Pott A, Metzner A, et al · · 2022 · cited 77× · PMID 34962134 · DOI 10.1161/circep.121.010516
Impact of cryoballoon application abortion due to phrenic nerve injury on reconnection rates: a YETI subgroup analysis.
Heeger CH, Popescu SȘ, Sohns C, Pott A, et al · · 2023 · cited 13× · PMID 36414239 · DOI 10.1093/europace/euac212

Verify or expand the search:

Other University of Luebeck trials

Trials by the same sponsor.

NCT06598280 — Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation · NA · recruiting
NCT06493994 — Myval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry · recruiting
NCT05846412 — Treatment of Functional Mitral Regurgitation in Patients With Atrial Fibrillation · NA · unknown
NCT05710822 — QDOT Based PVI for Atrial Fibrillation Treatment - The peQasus Study · unknown
NCT05563142 — Venous Vascular Closure System Versus Manual Compression Following Single Shot Device AF Ablation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03645577 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Luebeck
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03645577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing